Sage Therapeutics, Inc. is confident it can greatly expand the proportion of new mothers treated for postpartum depression (PPD) based on positive results from its Phase III study of zuranolone in the condition and the drug’s convenience as an oral medication. However, while the company is optimistic about the size of the PPD opportunity, there is some skepticism about how large it could be.
Sage/Biogen See Big Potential Market For Zuranolone In PPD
SKYLARK Meets Primary, Key Secondary Endpoints
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.
More from Strategy
More from Business
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.